Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds UBS Downgrades Newmont to Neutral, Lowers Price Target to $53

UBS Downgrades Newmont to Neutral, Lowers Price Target to $53

UBS analyst Cleve Rueckert downgrades Newmont (NYSE:NEM) from Buy to Neutral and lowers the price target from $59 to $53.

byBenzinga Newsdesk

February 14, 2023

1 minute read

UBS analyst Cleve Rueckert downgrades Newmont (NYSE:NEM) from Buy to Neutral and lowers the price target from $59 to $53.

What’s Going On With Palisade Bio (PALI) Stock?

By Henry Khederian

September 12, 10:44 AM

Palisade Bio Inc (NASDAQ: PALI) shares are trading lower by 6.1% to $0.69 Tuesday morning.

PALI

CareCloud’s medSR Division Successfully Implements MEDITECH Expanse EHR At Doctors Hospital Bahamas, Enhancing Patient Care And Data Resilience

By Benzinga Newsdesk

October 3, 9:02 AM

CareCloud, Inc. (NASDAQ:CCLD, CCLDP, CCLDO)))), a leader in healthcare technology services for medical practices and health systems nationwide, today announced its medSR division recently completed the successful

CCLD

SVB Leerink Maintains Market Perform on Genmab, Raises Price Target to $33

By Benzinga Newsdesk

November 10, 4:50 AM

SVB Leerink analyst Jonathan Chang maintains Genmab (NASDAQ:GMAB) with a Market Perform and raises the price target from $31 to $33.

GMAB

Analyst Ratings

8 Analysts Have This to Say About Stem

By Benzinga Insights

April 3, 12:00 PM

Over the past 3 months, 8 analysts have published their opinion on Stem (NYSE:STEM) stock. These analysts are…

STEM

UBS Downgrades Newmont to Neutral, Lowers Price Target to $53

Related Posts

What’s Going On With Palisade Bio (PALI) Stock?

CareCloud’s medSR Division Successfully Implements MEDITECH Expanse EHR At Doctors Hospital Bahamas, Enhancing Patient Care And Data Resilience

SVB Leerink Maintains Market Perform on Genmab, Raises Price Target to $33

8 Analysts Have This to Say About Stem